Trials / Completed
CompletedNCT01161667
Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Naratriptan Hydrochloride 2.5 mg Tablets Under Fasted Conditions
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Roxane Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study was to prove the bioequivalence of Naratriptan Hydrochloride Tablet under fasted conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | naratriptan hydrochloride | 2.5 mg tablet |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2007-09-01
- Completion
- 2007-09-01
- First posted
- 2010-07-13
- Last updated
- 2018-01-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01161667. Inclusion in this directory is not an endorsement.